species described in Section II of genus Flavobacterium which, however, involves heterogenous species.
Several investigators3,4,5), have recommended rearrangements of Flavobacterium species and proposed that Gram-negative, non-motile, non-gliding, non-spreading strains with low GC-content (<40%) are to belong to the genus Flavobacterium, while Gram-negative, non-motile or motile, peritrichous species with high GC content (60~70%) are to be transferred to the genus Empedobacter. In view of the morphological and physiological characteristics of G393-B445 and the new taxonomic criteria described above, strain G393-B445 is considered to belong to the genus Empedobacter.
Strain G393-B445 was clearly differentiated from the six species of Flavobacterium described in the BERGEY'S Manual on account at their physiological and biochemical properties. Flavobacterium antibioticum IFO-13715, which produces the peptide antibiotic BA-8436) , differs from strain G393-B445 in its non-motility, no growth at 37°C, negative hydrolysis of sucrose and other biochemical responses.
Strain G393-B445 has some similarities to a collagenolytic bacterium strain CRZV1 described as Empedobacter collagenolyticum, but is differentiated from the latter in the motility, alkali-sensitivity, growth in glucose -ammonium -salts medium, phosphatase activity and Tween hydrolysis7).
One of the common characteristics known for Empedobacter species is halotolerance (positive growth in 5.0% NaCl), whereas strain G393-B445 showed a distinct halophobic property. Therefore, strain G393-B445 was considered to be a new species of genus Empedobacter and designated Empedobacter haloabium sp. nov. The type strain is No. G393-B445 (single isolate); it was deposited in the American Type Culture Collection with the accession number ATCC 31962.
Antibiotic Production
A well-grown agar slant of strain G393-B445 was used to inoculate a seed medium composed of 2 % soluble starch, 1 % glucose, 0.2 % meat extract, 0.2 % yeast extract, 0.5 % NZ Case (Humko Scheffield Chemical) and 0.2% CaCO3, the pH being adjusted to 7.0 before sterilization. The seed culture was incubated at 28°C for 24 hours on a rotary shaker (250 rpm), and 5 ml of the growth was transferred to a 500-ml Erlenmeyer flask containing 100 ml of fermentation medium composed of 3% sucrose, 2 % linseed meal, 0.3%. (NH4)2SO4 and 0.5% CaCO3. The pH of the medium was adjusted to 7.0 before sterilization. The fermentation was carried out on a rotary shaker at 28°C and the antibiotic activity in fermentation broth followed by a paper disc-agar diffusion assay using Bacillus Table 3 . Sensitivity of strain G393-B445 to antibacterial agents (paper-disc method). Test procedure and sensitivity criteria follow those described in ref 14. *** units . Fermentation studies were also performed in 20-liter jar fermentors which contained 10 liters of the production medium having the same composition as described above. The fermentors were operated at 28°C with stirring at 250 rpm for 20~23 hours.
Isolation and Purification
The harvested broth (37 liters, 250 iig/ml) was acidified to pH 3.0 and stirred with an equal volume of 1-butanol for 1 hour. The 1-butanol layer was separated and evaporated to dryness. The residue was dissolved in methanol (100 ml) and the solution diluted with acetone (1 liter) to precipitate a crude solid (21 g) which was chromatographed on a column of Dowex I X 2 (CH3COO-type, 800 ml).
The column was developed successively with water (5 liters Table 4 . The elemental analysis of the antibiotic did not allow an unambiguous deduction of the molecular formula due to hydration. The values, nevertheless, pointed towards C49H79N11O195H2O which was later confirmed by the structural studies described in the accompanying paper9). Empedopeptin did not exhibit absorption maximum above 210 nm in the UV spectrum. The IR spectrum (Fig. 1) showed a polyhydroxyl absorption at around 3350 cm-1, an ester carbonyl at 1735 cm-1 and amide carbonyl bands at 1630 and 1540 cm-1.
The proton NMR spectrum of empedopeptin (Fig. 2) indicated a methyl group and several methylene and methine protons but no double bond proton.
Biological Properties
In Vitro Antibacterial Activity The minimum inhibitory concentrations (MICs) of empedopeptin were determined by a serial agar dilution method. Mueller-Hinton agar (Eiken) was always used for aerobic bacteria, GC medium (Eiken) for fastidious organisms, and GAM agar medium (Nissui) for anaerobic bacteria. Table 5 shows in vitro antibacterial activities of empedopeptin in comparison with amphomycin, an amphoteric peptide antibiotic, and vancomycin.
In general, the three antibiotics are similar in antibacterial spectra, inhibiting predominantly Grampositive aerobic and anaerobic bacteria. The intrinsic activity of empedopeptin was at least 2-fold Geometric mean of MIC (pg/ml) higher than that of amphomycin and about one-half that of vancomycin.
Empedopeptin
was compared with vancomycin for the activity against many strains of clinically important Gram-positive pathogens.
As shown in Table 6 , methicillin-resistant staphylococci were similarly susceptible to both antibiotics, vancomycin being approximately 2-fold more active than empedopeptin in terms of geometric mean MIC. Four strains of methicillin-resistant staphylococci were tested for the potential of resistance development to empedopeptin and vancomycin by successive subcultures in antibiotic-containing medium (Mueller-Hinton broth). As shown in Table 7 , the pattern of resistance development was similar for both antibiotics and the increase of the MIC values was in the range of 4 ~ 16 fold after 9 transfers.
In Vivo Activity
The in vivo efficacy of empedopeptin was assessed in experimental infections of mice produced by strains of sensitive and resistant staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae and Clostridium perfringens. Mice were challenged with a multiple of the lethal dose of the pathogens in a 5% suspension of hog gastric mucin (American Laboratory, Omaha, Neb.). Empedopeptin was dissolved in saline and administered to mice intramuscularly just before the bacterial challenge. The mice were observed for 5 days to determine the median protective dose (PD50). Amphomycin and vancomycin were comparatively tested as reference antibiotics. As shown in Table 8 , empedopeptin was more active in vivo than amphomycin but somewhat less active than vancomycin.
Blood Levels and Acute Toxicity
Blood levels were determined in mice following an intravenous or intramuscular administration of empedopeptin and vancomycin. Blood samples were collected from orbital sinuses and assayed by the paper disc-agar diffusion method using Micrococcus luteus PCI 1001 as the test organism. As shown in Table 9 , empedopeptin was well absorbed parenterally and gave much higher and more sustained blood levels than vancomycin.
Neither antibiotic was absorbed when administered orally.
The intravenous LD50 of empedopeptin to mice was found to be 560 mg/kg, while no death occurred up to a dose of 1,600 mg/kg by im route. a Peak blood level (gig/ml) . b Half life (hour) . C Area under the curve (Fig-hour/ml ).
